Cargando…

How we make cell therapy in Italy

In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemurro, Tiziana, Viganò, Mariele, Budelli, Silvia, Montelatici, Elisa, Lavazza, Cristiana, Marino, Luigi, Parazzi, Valentina, Lazzari, Lorenza, Giordano, Rosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548721/
https://www.ncbi.nlm.nih.gov/pubmed/26316716
http://dx.doi.org/10.2147/DDDT.S80403
_version_ 1782387221554266112
author Montemurro, Tiziana
Viganò, Mariele
Budelli, Silvia
Montelatici, Elisa
Lavazza, Cristiana
Marino, Luigi
Parazzi, Valentina
Lazzari, Lorenza
Giordano, Rosaria
author_facet Montemurro, Tiziana
Viganò, Mariele
Budelli, Silvia
Montelatici, Elisa
Lavazza, Cristiana
Marino, Luigi
Parazzi, Valentina
Lazzari, Lorenza
Giordano, Rosaria
author_sort Montemurro, Tiziana
collection PubMed
description In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene therapy, and tissue engineered products, as a new class of drugs. Their manufacture requires the same pharmaceutical framework as for conventional drugs and this means that industrial, large-scale manufacturing process has to be adapted to the peculiar characteristics of cell-containing products. Our hospital took up the challenge of this new path in the early 2000s; and herein we describe the approach we followed to set up a pharmaceutical-grade facility in a public hospital context, with the aim to share the solutions we found to make cell therapy compliant with the requirements for the production and the quality control of a high-standard medicinal product.
format Online
Article
Text
id pubmed-4548721
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45487212015-08-27 How we make cell therapy in Italy Montemurro, Tiziana Viganò, Mariele Budelli, Silvia Montelatici, Elisa Lavazza, Cristiana Marino, Luigi Parazzi, Valentina Lazzari, Lorenza Giordano, Rosaria Drug Des Devel Ther Methodology In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene therapy, and tissue engineered products, as a new class of drugs. Their manufacture requires the same pharmaceutical framework as for conventional drugs and this means that industrial, large-scale manufacturing process has to be adapted to the peculiar characteristics of cell-containing products. Our hospital took up the challenge of this new path in the early 2000s; and herein we describe the approach we followed to set up a pharmaceutical-grade facility in a public hospital context, with the aim to share the solutions we found to make cell therapy compliant with the requirements for the production and the quality control of a high-standard medicinal product. Dove Medical Press 2015-08-20 /pmc/articles/PMC4548721/ /pubmed/26316716 http://dx.doi.org/10.2147/DDDT.S80403 Text en © 2015 Montemurro et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Methodology
Montemurro, Tiziana
Viganò, Mariele
Budelli, Silvia
Montelatici, Elisa
Lavazza, Cristiana
Marino, Luigi
Parazzi, Valentina
Lazzari, Lorenza
Giordano, Rosaria
How we make cell therapy in Italy
title How we make cell therapy in Italy
title_full How we make cell therapy in Italy
title_fullStr How we make cell therapy in Italy
title_full_unstemmed How we make cell therapy in Italy
title_short How we make cell therapy in Italy
title_sort how we make cell therapy in italy
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548721/
https://www.ncbi.nlm.nih.gov/pubmed/26316716
http://dx.doi.org/10.2147/DDDT.S80403
work_keys_str_mv AT montemurrotiziana howwemakecelltherapyinitaly
AT viganomariele howwemakecelltherapyinitaly
AT budellisilvia howwemakecelltherapyinitaly
AT montelaticielisa howwemakecelltherapyinitaly
AT lavazzacristiana howwemakecelltherapyinitaly
AT marinoluigi howwemakecelltherapyinitaly
AT parazzivalentina howwemakecelltherapyinitaly
AT lazzarilorenza howwemakecelltherapyinitaly
AT giordanorosaria howwemakecelltherapyinitaly